Login to Your Account



ViroPharma to Acquire Lev Paying $443M Up Front

By Donna Young


Wednesday, July 16, 2008
Antibiotic maker ViroPharma Inc. is acquiring Lev Pharmaceuticals Inc. for $442.9 million up front, or $2.75 per share. The deal has a potential net aggregate value of up to $617.5 million if certain milestones are met. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription